Allergic conjunctivitis is a common and potentially debilitating condition affecting the conjunctiva, eyelids and cornea, and it is often associated with nonocular symptoms and signs of rhinitis or sinusitis.
See you next year in Seattle!
Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761)
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical
Ophthalmic Product Development Insights
How to approach the occasional situation in which this chronic condition suddenly becomes acute.
Deviations should be rare. The protocol helps to keep the study on track.
Customer Success Stories: Celebrating Your Big Wins in 2014-2015
SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndr
U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc.